Study pembrolizumab and lenvatinib for advanced vulvar cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult woman (18 or older).
- Have vulvar squamous cell cancer that is recurrent, persistent, or metastatic—or locally advanced and not curable with surgery or definitive (chemo)radiation.
- Have had no more than 2 prior chemotherapy treatments for your recurrent or metastatic cancer.
- Have at least one measurable tumor spot on scans, including allowed cases in previously treated radiation areas if there’s evidence it grew.
- Be well enough for treatment, with ECOG performance status 0 to 1 (generally able to do self-care and most daily activities).
- Have tumor tissue available for testing (archived sample and/or a new biopsy), and meet required blood/organ function limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for women with advanced vulvar cancer that cannot be surgically removed or has spread. The goal is to see if this combination can shrink or control the cancer.
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for women whose endometrial cancer has returned after initial treatment with immunotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests whether adding two drugs—pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy)—to the standard chemoradiation and brachytherapy can improve outcomes for women with high-risk locally advanced cervical cancer. The goal is to see if this combination helps control the cancer better than usual treatment.
This Phase 2 study looks at how vulvar squamous cell cancer (SCC) spreads to the sentinel lymph node, and how findings may guide treatment. It focuses on specific early-stage tumor features and requires that cancer is found in the sentinel lymph node.
Hear when a new Recurrent Vulvar Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.